Company intelligence / Profile preview

Vitae International

Fort Washington, Pennsylvania, United Statesvitaeintl.com ↗

Ownership: Private
Development stage: Other

Overview

Vitae developed several first-in-class small molecule candidates targeting dermatologic and autoimmune diseases. Its lead program VTP‑43742 showed positive Phase II proof-of-concept results in moderate-to-severe psoriasis. Other programs included topical agents for atopic dermatitis and BACE inhibitors for Alzheimer’s disease. Some programs were discontinued post-acquisition.

Therapeutic areas: NeurologyDermatologyEndocrinologyImmunologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Boehringer Ingelheim – BACE inhibitor collaboration ($14M milestone payment earned pre-acquisition)

Beyond the preview

Go deeper on Vitae International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitae International.

Explore the full profile